Synthesis of novel tetrahydro[4,5]imidazo[2,1-b]-chromeno[4,3,2-de] quinazoline and benzothiazol-2-ylaminoxanthenone derivatives

Article abstract of DOI:10.3987/COM-11-12201

Some novel tetrahydroquinazoline and xanthenone derivatives were synthesized from the reaction of dimedone and Schiff base in the presence of sulfamic acid in good yields. The Japan Institute of Heterocyclic Chemistry.

Full text of DOI:10.3987/COM-11-12201

HETEROCYCLES, Vol. 83, No. 8, 2011
1831
HETEROCYCLES, Vol. 83, No. 8, 2011, pp. 1831 - 1841. © The Japan Institute of Heterocyclic Chemistry
Received, 6th March, 2011, Accepted, 30th May, 2011, Published online, 7th June, 2011
DOI: 10.3987/COM-11-12201
SYNTHESIS
OF
NOVEL
TETRAHYDRO[4,5]IMIDAZO[2,1-b]-
CHROMENO[4,3,2-de]QUINAZOLINE
AND
BENZOTHIAZOL-2-
YLAMINOXANTHENONE DERIVATIVES
Mina Saeedi,* Yahya S. Beheshtiha, Majid M. Heravi,* and Hossein A.
Oskooie
Department of Chemistry, School of Sciences, Alzahra University, PO Box
1993891176, Vanak, Tehran, Iran (e-mail:
mmh1331@yahoo.com)
saeedi.mina@gmail.com and
Abstract – Some novel tetrahydroquinazoline and xanthenone derivatives were
synthesized from the reaction of dimedone and Schiff base in the presence of
sulfamic acid in good yields.
Heterocycles containing nitrogen and oxygen are important targets in medicinal chemistry. The
quinazoline ring system along with many alkaloids is a widely recognized moiety in organic syntheses
and medicinal application.1-3 It has been reported that quinazoline derivatives possess interesting
biological activities, such as anticonvulsant, antibacterial, antidiabetic and anticancer properties.4 Many
quinazolines have been found to inhibit kinases by competing with ATP for the kinase active site.5 Large
numbers of quinazolinones have been synthesized or isolated from plants, animals and microorganisms6
and also in several areas as materials in electronics, in electrochemistry as anticorrosive agents, as
polymers or optical materials and fluorescent tags in DNA sequencing.7,8 It was reported that
benzimidazo-quinazoline derivatives show various therapeutic activities, such as anticancer,9 antiviral,10
antimicrobial,11 anti-inflammatory12 and anticonvulsants.13
Xanthenone derivatives have been reported to possess interesting cytotoxic activities.14,15 They are
reported to possess antileukemic, antitumor, antiulcer, antimicrobial, antihepatotoxic and CNS-depressant
activities.16,17 Therefore, development of efficient preparation of novel quinazoline and xanthenone
derivatives is an interesting challenge.

1832
HETEROCYCLES, Vol. 83, No. 8, 2011
Recently we have developed synthesis of new heterocyclic compounds in the presence of sulfamic acid
(SA) as an efficient and useful catalyst.18-20 Sulfamic acid is a common sulfur-containing amino acid with
mild acidity. It is green, inexpensive, easy to handle, non toxic, available and efficient catalyst for various
organic chemistry transformations and its use has been growing rapidly.21
In the context of our interest in designing new ways for synthesis of heterocyclic compounds,18-20,22
herein, we have developed
a
novel and convenient approach to synthesize new
and benzothiazol-2-ylamino-
tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazoline
xanthenone derivatives via reaction of dimedone 1 and Schiff bases 2 and 7 catalyzed by sulfamic acid
(Schemes 1 and 3).
R2
R1
R3
N
O
NH
sulfamic acid (30 mol%)
MeCN, reflux, 2.5-3.5 h
O
R3
R2
N
N
OH
O
N
N
R1
1
2
3
R1 = H, OH, OMe
R2 = H, OH, OMe
R3 = H, NO2, Br
Scheme 1. Synthesis of tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazoline derivatives 3
We initially used the most direct approach, a Biginelli-type condensation and subjected dimedone 1,
salicylaldehyde 4 and 2-aminobenzimidazole 5 to a one-pot three-component reaction as a model reaction
(Scheme 2). Then the model reaction was carried out under different conditions. Some conditions and
results are summarized in Table 1.
O
OH
O
CHO
OH
O
H
N
NH2
N
O
O
1
4
5
6 exclusive
Scheme 2. Investigation of one-pot three-component reaction of dimedone 1, salicylaldehyde 4 and
2-aminobenzimidazole 5, under different conditions as can be seen in Table 1
At first we studied the reaction in solvent-free conditions (Table 1, entries 1 and 3). Any products were
not obtained at ambient condition or evaluated temperatures (100 °C). When the model reaction
performed under solvent-free condition at 100 °C in the presence of sulfamic acid (30 mol%), product 6

HETEROCYCLES, Vol. 83, No. 8, 2011
1833
was exclusively isolated as proved by physical and spectral characterization.23 The results show that
2-aminobenzimidazole has not participated in the reaction. It is worthy to mention that when the model
reaction was carried out in different solvents in the presence of a variety of catalysts as can be seen in
Table 1, same product was detected and there was no evidence for formation of desired product. We also
applied microwave irradiation to the model reaction and 6 was isolated as the only product (Table 1).
Table 1. Investigation of various conditions for a one-pot three-component reaction of dimedone 1,
salicylaldehyde 4 and 2-aminobenimidazole 5
Entry
Conditions
Catalyst
Time
12 h
Yield of 6 (%)a
1
2
3
4
solvent free (100 °C)
MW irradiation (500 W)
solvent free (100 °C)
-
0
5
-
6 min
12 h
sulfamic acid (30 mol%)
45
30
MW irradiation (400 W) sulfamic acid (30 mol%)
7 min
K2CO3 (36 mol%)
MeCN (reflux)
5
6
8 h
10 h
5 h
45
25
55
50
30
35
PTSA (17 mol%)
MeCN (reflux)
I2 (40 mol%)
EtOH (reflux)
7
I2 (40 mol%)
8
MeCN (reflux)
5 h
K2CO3 (36 mol%)
toluene (reflux)
9
8 h
sulfamic acid (30 mol%)
CH2Cl2 (reflux)
10
8 h
a Isolated yields.
To overcome this apparent failure, another alternative synthetic route was designed. For this purpose,
various Schiff bases 2 were prepared by reaction of salicylaldehyde 4 and its derivatives with
2-aminobenzimidazole 5. We tried to prepare the corresponding Schiff bases 2 via reported
procedures,24,25 we could not prepare them however in high yields. We found that under microwave
conditions, condensation reaction could proceed very fast and efficiently. A mixture of salicylaldehyde
derivative (1 mmol) and 2-aminobenzimidazole (1 mmol) in methanol (5 mL) was irradiated in
microwave oven (700 W/ 7 min). After cooling to room temperature, the precipitate was collected,
washed three times with cold methanol. In most cases, Schiff bases were analytically pure without
recrystallization however they can be crystallized from methanol.

1834
HETEROCYCLES, Vol. 83, No. 8, 2011
Next the reaction of dimedone and Schiff base was investigated. As can be seen in Table 2, to optimize
the reaction conditions, the Schiff base of salicylaldehyde and 2-aminobenzimidazole was treated with
dimedone 1 under different reaction conditions to form the corresponding product 3a (Scheme 1). The
best result was obtained in the presence of 30 mol% sulfamic acid in MeCN under reflux condition. It is
also to be noted that any undesired products were not observed.
Table 2. Investigation of various conditions on synthesis of 3a by the reaction of 1 and 2
Entry
Conditions
Catalyst
Time
Yield of 3a (%)a
solvent free (100 °C)
-
24 h
0
1
MW irradiationb
solvent free (100 °C)
MW irradiationb
MeCN (reflux)
-
10 min
9 h
0
2
3
sulfamic acid (30 mol%)
45
0
sulfamic acid (30 mol%) 10 min
4
sulfamic acid (30 mol%)
3.5 h
12 h
9 h
70
30
55
55
35
55
50
5
MeCN (room temperature) sulfamic acid (30 mol%)
6
EtOH (reflux)
MeCN (reflux)
MeCN (reflux)
MeCN (reflux)
MeCN (reflux)
sulfamic acid (30 mol%)
K2CO3 (36 mol%)
ZnCl2 (37 mol%)
I2 (40 mol%)
7
12 h
12 h
12 h
10 h
8
9
10
11
KF-Al2O3 (0.1 g)
aIsolated yields.
b Different powers, 200 W, 300 W, 400 W and 500 W were examined.
The model reaction was achieved under microwave irradiation and different power inputs were examined.
It was found that no product was obtained even in the presence of sulfamic acid. We also investigated the
effect of other catalysts such as I2, ZnCl2 and KF/Al2O3 and in all case the desired product was not
obtained. In order to expand the scope of the present work, various Schiff bases 2 were examined and
desired products were obtained in good yields. The results are summarized in Table 3.
Proposed mechanism for the synthesis of tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno-
[4,3,2-de]quinazoline derivatives 3 can be explained in Scheme 3, based on reference26 that discussed
reaction of imines and dimedone.

HETEROCYCLES, Vol. 83, No. 8, 2011
1835
Table 3. Synthesis of 3 by the reaction of 1 and 2
Entry
1
R1
H
R2
H
R3
H
Product
Time (h)
3.5
Yield (%)a
70
3a
OMe
H
H
OMe
H
H
H
3b
3c
3d
3e
3f
3
75
70
70
65
85
80
2
3
4
5
6
7
3.5
3.5
3.5
2.5
3
OH
H
H
OH
H
H
H
NO2
Br
H
H
3g
aIsolated yields
R
R
HO
O
HO
O
O
N
sulfamic acid
MeCN, reflux
NH
N
N
N
N
H2N
O
O
N
N
H
O
H2N
OH
R
1
2
R
N
R
N
NH2
NH2
O
O
O
N
O
-H2O
N
-H2O
N
N
N
N
N
H
O
R
O
OH2
R
OH2
3
Scheme 3. Proposed mechanism for the synthesis of tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno-
[4,3,2-de]quinazoline derivatives 3
We next prepared Schiff bases derived from 2-aminothiazole and salicylaldehyde derivatives. General
procedure is the same as described for compounds 2. Under optimized conditions, reaction of dimedone 1
and mentioned Schiff bases 7 were examined. In this case, interestingly corresponding
tetrahydro-1H-1-xanthenone derivatives were formed (Scheme 4). In order to show the generality and
scope of this new protocol, reaction of dimedone 1 and Schiff bases 7 were conducted in the presence of
30 mol% sulfamic acid under reflux condition and related tetrahydro-1H-1-xanthenone derivatives were
obtained in good yields. Corresponding data are shown in Table 4.

1836
HETEROCYCLES, Vol. 83, No. 8, 2011
R2
R3
R1
N
S
O
O
S
N
sulfamic acid (30 mol%)
N
R3
R2
N
H
MeCN, reflux, 3-3.5 h
OH
O
O
R1
1
7
8
R1 = H, OMe
R2 = H, OH
R
3 = H, NO2, Br
Scheme 4. Synthesis of benzothiazol-2-ylaminoxanthenone derivatives
Table 4. Synthesis of 8 by the reaction of 1 and 7
Entry
1
R1
H
R2
H
R3
H
Product
Time (h)
3
Yield (%)a
75
8a
OMe
H
H
OH
H
H
H
8b
8c
8d
8e
3.5
3.5
3
70
70
85
80
2
3
4
5
H
NO2
Br
H
H
3
aIsolated yields
In conclusion, we have described a new and efficient procedure for the preparation of novel
tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazoline and tetrahydro-1H-1-xanthenone
derivatives via reaction of dimedone and Schiff base in the presence catalytic amount of sulfamic acid in
MeCN under reflux condition. The procedure was simple and products were obtained in good yields.
EXPERIMENTAL
Melting points were measured, using a capillary tube method with a Bamstead Electrothermal 9200
13
apparatus. 1H and C NMR spectra were recorded on a Bruker AQS-AVANCE spectrometer at 500 and
125 MHz, using TMS as an internal standard. FTIR spectra were recorded using, KBr disks on FT-IR
Bruker Tensor 27 instrument. Mass spectra were documented on an Agilent Technology (HP) mass
spectrometer operating at an ionization potential of 70 eV. The elemental analysis was performed with an
Elemetar Analysensystem GmbH VarioEL CHNS mode.
General procedure for the synthesis of compounds 3a-g and 8a-e

HETEROCYCLES, Vol. 83, No. 8, 2011
1837
A mixture of dimedone (1.2 mmol), Schiff base (1 mmol), sulfamic acid (30 mol%) and MeCN (5 mL) was
heated at reflux for indicated time as required to complete the reaction (Table 3). Upon completion of the
reaction, monitored by TLC, the mixture was cooled to room temperature. The precipitated product was
separated by filtration, washed with water and acetone. Corresponding products were analytically pure
without recrystallization.
7,7-Dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazoline (3a)
Compound 3a was obtained as white powder. Mp 185-186 °C. FTIR (KBr, cm-1) νmax: 3067, 2957, 1682,
1
1615. H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.21 (m, 4H, CH2), 6.12 (s, 1H, CH),
6.78-8.35 (m, 8H, Ar). 13C NMR (125 MHz DMSO-d6) δC: 29.4, 32.1, 38.9, 49.8, 50.9, 53.0, 109.2, 110.2,
111.0, 118.1, 118.9, 123.1, 123.9, 125.9, 126.2, 127.4, 132.3, 140.1, 152.2, 154.0, 155.2, 165.0. MS m/z:
341 [M]+. Anal. Calcd for C22H19N3O: C, 77.40; H, 5.61; N, 12.31. Found: C, 77.65; H, 5.95; N, 12.11.
4-Methoxy-7,7-dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinozaline
(3b)
Compound 3b was obtained as white powder. Mp 274-275 °C. FTIR (KBr, cm-1) νmax: 3113, 2884, 1691,
1634 cm-1. 1H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.20 (m, 4H, CH2), 3.78 (s, 3H, CH3),
6.06 (s, 1H, CH), 6.69-8.35 (m, 7H, Ar). 13C NMR (125 MHz, DMSO-d6) δC: 28.9, 32.3, 38.7, 50.5, 51.1,
53.2, 57.2, 109.9, 110.3, 113.0, 118.1, 120.9, 124.9, 125.9, 126.3, 127.0, 132.9, 140.1, 144.8, 152.3, 154.2,
156.3, 165.3. MS m/z: 371 [M]+. Anal. Calcd for C23H21N3O2: C, 74.37; H, 5.70; N, 11.31. Found: C,
74.66; H, 5.95; N, 11.57.
3-Methoxy-7,7-dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinozaline
(3c)
Compound 3c was obtained as white powder. Mp 277-278 °C. FTIR (KBr, cm-1) νmax: 3115, 1688, 1630
cm-1. 1H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.21 (m, 4H, CH2), 3.84 (s, 3H, CH3), 6.15 (s,
13
1H, CH), 6.61-8.33 (m, 7H, Ar). C NMR (125 MHz, DMSO-d6) δC: 28.3, 32.4, 38.7, 50.4, 51.1, 53.4,
57.1, 110.0, 110.2, 112.7, 118.2, 120.9, 124.8, 125.7, 126.3, 127.1, 133.2, 140.1, 144.4, 152.3, 154.2,
156.4, 166.3. MS m/z: 371 [M]+. Anal. Calcd for C23H21N3O2: C, 74.37; H, 5.70; N, 11.31. Found: C,
74.01; H, 6.05; N, 10.97.
7,7-Dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazolin-4-ol (3d)
Compound 3d was obtained as light brown powder. Mp 282-283 °C. FTIR (KBr, cm-1) νmax: 3440, 2950,
1680, 1625 cm-1. 1H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.21 (m, 4H, CH2), 6.05 (s, 1H,

1838
HETEROCYCLES, Vol. 83, No. 8, 2011
13
CH), 6.90-8.32 (m, 7H, Ar), 10.45 (s, 1H, OH). C NMR (125 MHz, DMSO-d6) δC: 29.1, 32.4, 38.7,
49.5, 50.1, 51.3, 109.2, 110.3, 117.1, 119.1, 119.9, 122.0, 122.3, 123.4, 124.1, 128.2, 133.8, 145.0, 146.2,
151.5, 155.5, 165.5. MS m/z: 357 [M]+. Anal. Calcd for C22H19N3O2: C, 73.93; H, 5.36; N, 11.76. Found:
C, 73.65; H, 5.25; N, 11.91.
7,7-Dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazolin-3-ol (3e)
Compound 3e was obtained as orange powder. Mp 280-282 °C. FTIR (KBr, cm-1) νmax: 3437, 2957, 1698,
1
1620 cm-1. H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.20 (m, 4H, CH2), 6.05 (s, 1H, CH),
13
6.71-8.33 (m, 7H, Ar), 10.26 (s, 1H, OH). C NMR (125 MHz, DMSO-d6) δC: 29.1, 32.5, 38.5, 49.7,
50.3, 51.4, 109.1, 110.1, 117.3, 119.2, 120.0, 122.3, 122.5, 123.2, 124.2, 128.1, 133.6, 145.2, 146.1, 151.5,
155.5, 166.5. MS m/z: 357 [M]+. Anal. Calcd for C22H19N3O2: C, 73.93; H, 5.36; N, 11.76. Found: C,
74.21; H, 5.41; N, 11.38.
2-Nitro-7,7-dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazoline (3f)
Compound 3f was obtained as white powder. Mp 284 °C. FTIR (KBr, cm-1) νmax: 3188, 2958, 1672, 1615,
1581, 1378 cm-1. 1H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.20 (m, 4H, CH2), 6.25 (s, 1H,
CH), 6.83-8.32 (m, 7H, Ar). 13C NMR (125 MHz, DMSO-d6) δC: 29.1, 32.4, 38.6, 49.5, 50.1, 53.2, 109.9,
112.2, 112.3, 118.1, 123.0, 123.3, 123.6, 124.9, 129.2, 132.7, 138.9, 140.0, 151.6, 154.1, 155.3, 164.8.
MS m/z: 386 [M]+. Anal. Calcd for C22H18N4O3: C, 68.38; H, 4.70; N, 14.50. Found: C, 68.62; H, 4.43; N,
14.30.
2-Bromo-7,7-dimethyl-6,7,8,15a-tetrahydrobenzo[4,5]imidazo[2,1-b]chromeno[4,3,2-de]quinazoline
(3g)
Compound 3g was obtained as white powder. Mp 206-207 °C. FTIR (KBr, cm-1) νmax: 3188, 2960, 1675,
1
1616 cm-1. H NMR (500 MHz, DMSO-d6) δH: 1.02 (s, 6H, CH3), 2.21 (m, 4H, CH2), 6.05 (s, 1H, CH),
6.70-8.38 (m, 7H, Ar). 13C NMR (125 MHz, DMSO-d6) δC: 29.1, 33.0, 38.5, 49.2, 50.6, 52.4, 109.8,
112.1, 112.2, 118.1, 122.9, 123.4, 124.1, 124.9, 129.5, 133.0, 139.0, 140.0, 151.2, 152.1, 153.1, 164.8.
MS m/z: 419 [M]+. Anal. Calcd for C22H18BrN3O: C, 62.87; H, 4.32; N, 10.00. Found: C, 63.16, H, 3.98;
N, 10.28.
9-(1,3-Benzothiazol-2-ylamino)-3,3-dimethyl-2,3.4.9-tetrahydro-1H-1-xanthenone (8a)
Compound 8a was obtained as pale yellow powder. Mp 277 °C. FTIR (KBr, cm-1) νmax: 3439, 2960, 1621,
1
1574 cm-1. H NMR (500 MHz, DMSO-d6) δH: 0.96 (s, 3H, CH3), 1.11 (s, 3H, CH3), 2.11 (d, J = 15.75
Hz, 1H, CH2), 2.27 (d, J = 15.10 Hz, 1H, CH2), 2.45 (d, J = 16.38 Hz, 1H, CH2), 2.56 (d, J = 15.10 Hz,

HETEROCYCLES, Vol. 83, No. 8, 2011
1839
13
1H, CH2), 6.50 (s, 1H, CH), 6.90-8.45 (m, 8H, Ar), 11.70 (s, 1H, NH). C NMR (125 MHz, DMSO-d6)
δC: 27.3, 29.4, 33.5, 46.3, 52.1, 54.0, 112.1, 119.3, 123.6, 124.4, 124.9, 126.9, 127.3, 128.1, 128.3, 139.0,
139.8, 144.3, 159.8, 161.0, 165.5, 194.0. MS m/z: 376 [M]+. Anal. Calcd for C22H20N2O2S: C, 70.19; H,
5.35; N, 7.44. Found: C, 69.95; H, 5.50; N, 7.78.
9-(1,3-Benzothiazol-2-ylamino)-5-methoxy-3,3-dimethyl-2,3,4,9,-tetrahydro-1H-1-xanthenone (8b)
Compound 8b was obtained as pale pink powder. Mp 226-227 °C. FTIR (KBr, cm-1) νmax: 3409, 2954,
1
1642, 1585 cm-1. H NMR (500 MHz, DMSO-d6) δH: 0.96 (s, 3H, CH3), 1.11 (s, 3H, CH3), 2.11 (d, J =
15.70 Hz, 1H, CH2), 2.30 (d, J = 15.11 Hz, 1H, CH2), 2.48 (d, J = 16.30 Hz, 1H, CH2), 2.53 (d, J = 15.08
Hz, 1H, CH2), 3.84 (s, 3H, CH3), 6.48 (s, 1H, CH), 6.80-8.42 (m, 7H, Ar), 11.75 (s, 1H, NH). 13C NMR
(125 MHz, DMSO-d6) δC: 27.1, 29.3, 33.5, 45.6, 51.3, 53.5, 57.8, 111.5, 116.3, 121.2, 121.6, 125.4, 126.1,
127.3, 128.0, 128.1, 137.1 140.0, 140.3, 161.3, 163.0, 166.7, 194.5. MS m/z: 406 [M]+. Anal. Calcd for
C23H22N2O3S: C, 67.96, H, 5.46; N. 6.89. Found: C, 68.25; H, 5.15; N, 7.11.
9-(1,3-Benzothiazol-2-ylamino)-6-hydroxy-3,3-dimethyl-2,3,4,9,-tetrahydro-1H-1-xanthenone (8c)
Compound 8c was obtained as pale yellow powder. Mp 240-242 °C. FTIR (KBr, cm-1) νmax: 3415, 2960,
1
1640, 1570 cm-1. H NMR (500 MHz, DMSO-d6) δH: 0.96 (s, 3H, CH3), 1.11 (s, 3H, CH3), 2.10 (d, J =
15.71 Hz, 1H, CH2), 2.28 (d, J = 15.09 Hz, 1H, CH2), 2.45 (d, J = 16.39 Hz, 1H, CH2), 2.60 (d, J = 15.07
13
Hz, 1H, CH2), 6.52 (s, 1H, CH), 6.72-8.41 (m, 7H, Ar), 11.65 (s, 2H, NH, OH). C NMR (125 MHz,
DMSO-d6) δC: 27.1, 29.5, 33.3, 44.9, 51.8, 53.8, 115.0, 119.1, 123.6, 124.7, 124.9, 126.9, 127.1, 127.9,
128.1, 136.6, 139.1, 141.2, 158.3, 164.2, 166.6, 194.8. MS m/z: 392 [M]+. Anal. Calcd for C22H20N2O3S:
C, 67.33; H, 5.14; N, 7.14. Found: C, 67.65; H, 4.86; N, 6.86.
9-(1,3-Benzothiazol-2-ylamino)-3,3-dimethyl-7-nitro-2,3,4,9,-tetrahydro-1H-1-xanthenone (8d)
Compound 8d was obtained as yellow powder. Mp 286-287 °C. IR (KBr, cm-1) νmax: 3443, 3063, 1625,
1
1588, 1387 cm-1. H NMR (500 MHz, DMSO-d6) δH: 0.96 (s, 3H, CH3), 1.11 (s, 3H, CH3), 2.10 (d, J =
15.73 Hz, 1H, CH2), 2.29 (d, J = 15.06 Hz, 1H, CH2), 2.44 (d, J = 16.36 Hz, 1H, CH2), 2.58 (d, J = 15.05
Hz, 1H, CH2), 6.81 (s, 1H, CH), 6.92-8.48 (m, 7H, Ar), 11.71 (s, 1H, NH). 13C NMR (125 MHz,
DMSO-d6) δC: 27.4, 29.8, 33.1, 45.5, 51.2, 53.3, 113.1, 117.0, 123.4, 123.7, 125.0, 126.4, 127.4, 127.5,
127.8, 138.9, 139.2, 140.1, 160.0, 162.2, 165.9, 194.9. MS m/z: 421 [M]+. Anal. Calcd for C22H19N3O4S:
C, 62.69; H, 4.54; N, 9.97. Found: C, 62.40; H, 4.77; N, 10.25.
9-(1,3-Benzothiazol-2-ylamino)-7-bromo-3,3-dimethyl-2,3,4,9,-tetrahydro-1H-1-xanthenone (8e)
Compound 8e was obtained as pale yellow powder. Mp 242-243 °C. FTIR (KBr, cm-1) νmax: 3440, 3103,

1840
HETEROCYCLES, Vol. 83, No. 8, 2011
2962, 1617, 1570 cm-1. 1H NMR (500 MHz, DMSO-d6) δH: 0.96 (s, 3H, CH3), 1.11 (s, 3H, CH3), 2.12 (d,
J = 15.81 Hz, 1H, CH2), 2.27 (d, J = 15.10 Hz, 1H, CH2), 2.45 (d, J = 16.21 Hz, 1H, CH2), 2.56 (d, J =
13
15.10 Hz, 1H, CH2), 6.40 (s, 1H, CH), 6.60-8.45 (m, 7H, Ar), 11.70 (s, 1H, NH). C NMR (125 MHz,
DMSO-d6) δC: = 27.2, 29.4, 33.1, 45.2, 51.2, 53.3, 113.1, 117.0, 123.4, 123.7, 125.0, 126.8, 127.0, 127.8,
127.9, 139.0, 139.3, 140.7, 160.4, 162.2, 165.7, 194.7. MS m/z: 454 [M]+. Anal. Calcd for
C22H19BrN2O2S: C, 58.03; H, 4.21; N, 6.15. Found: C, 58.33; H, 4.51; N, 5.90.
ACKNOWLEDGEMENTS
We gratefully acknowledge the partial financial support from Alzahra University Research Council.
REFERENCES
1. G. G. Spence, E. C. Taylor, and O. Buchardt, Chem. Rev., 1970, 70, 231.
2. P. Zhichkin, E. Kesicki, J. Treiberg, L. Bourdon, M. Ronsheim, H. C. Ooi, S. T. White, A. Judkins, and
D. Fairfax, Org. Lett., 2007, 9, 1415.
3. M. A. H. Ismail, S. Barker, D. A. Abou El Ella, K. A. M. Abouzid, R. A. Toubar, and M. H. Todd, J.
Med. Chem., 2006, 49, 1526.
4. N. Touroutoglou and R. Pazdur, Clin. Cancer Res., 1996, 2, 227; A. L. Jackman, F. T. Boyle, and K. R.
Harrap, New Drug, 1996, 14, 305; T. M. Sielecki, T. L. Johnson, J. Liu, J. K. Muckelbauer, R. H.
Grafstrom, S. Cox, J. Boylan, C. R. Burton, H. Chen, A. Smallwood, C. H. Chang, M. Boisclair, P. A.
Benfield, G. L. Trainora, and S. P. Seitza, Bioorg. Med. Chem. Lett., 2001, 11, 1157; K. Matsuno, M.
Ichimura, T. Nakajima, K. Tahara, S. Fujiwara, H. Kase, J. Ushiki, N. A. Giese, A. Pandey, R. M.
Scarborough, N. A. Lokker, J.-C. Yu, J. Irie, E. Tsukuda, S.-I. Ide, S. Oda, and Y. Nomoto, J. Med.
Chem., 2002, 45, 3057.
5. V. Kumar, C. Mohan, M. Gupta, and M. P. Mahajan, Tetrahedron, 2005, 61, 3533.
6. S. B. Mhaske and N. P. Argade, J. Org. Chem., 2001, 66, 9038.
7. K. P. Chan, H. Yang, and A. S. Hay, J. Polym. Sci., 1996, 34, 1923.
8. C. J. Daly, C. M. Milligan, G. Milligan, J. F. Mackenzie, and J. C. Mcgrath, J. Pharmacol. Exp. Ther.,
1998, 286, 984.
9. L. D. Via, O. Gia, S. M. Mango, A. D. Settimo, A. M. Marini, G. Primofiore, F. D. A. Settimo, and S.
Salerno, Farmaco, 2001, 56, 159.
10. A. A. Spasov, I. N. Yozhitsa, L. I. Bugaeva, and V. A. Anisimova, Pharma. Chem. J., 1999, 33, 232.
11. B. A. Insuasty, H. Torres, J. Quiroga, R. Abonia, R. Rodriguez, M. Nogueras, A. Sanchez, C. Saitz, S. L.
Alvarez, and S. A. Zacchino, J. Chil. Chem. Soc., 2006, 51, 927.
12. G. D. Galarcei, R. E. Foncea, A. M. Edwards, H. Pessoamahana, C. D. P. Mahana, and R. A.

HETEROCYCLES, Vol. 83, No. 8, 2011
1841
Ebenspergeri, Biol. Res., 2008, 41, 43.
13. L. N. Vostrova, T. A. Voronina, T. L. Karaseva, S. A. Gernega, E. I. Ivanov, A. M. Kirichenko, and M.
Yu. Totrova, Pharma. Chem. J., 1986, 20, 404.
14. A. Banerji, A. D. Deshpande, B. R. Prabhu, and P. Pradhan, J. Nat. Prod., 1994, 57, 396.
15. J. P. Horwitz, I. Massova, T. E. Wiese, B. H. Besler, and T. H. Corbett, J. Med. Chem., 1994, 37, 781.
16. R. T. Scannell and R. Stevenson, J. Heterocycl. Chem., 1986, 23, 857.
17. C. Gopalakrishnan, D. Shankaranarayanan, S. K. Nazimudeen, and L. Kameswaran, Ind. J. Pharmacol.,
1980, 12, 181.
18. M. M. Heravi, M. Saeedi, Y. S. Beheshtiha, and H. A. Oskooie, Mol. Divers., 2010, in press.
19. M. M. Heravi, H. Alinejhad, K. Bakhtiari, and H. A. Oskooie, Mol. Divers., 2010, 14, 621.
20. M. M. Heravi, M. Saeedi, Y. S. Beheshtiha, and H. A. Oskooie, Heterocycles, 2011, 83, 535.
21. M. M. Heravi, B. Baghernejad, and H. A. Oskooie, Curr. Org. Chem., 2009, 13, 1002.
22. M. Saeedi, M. M. Heravi, Y. S. Beheshtiha, and H. A. Oskooie, Tetrahedron, 2010, 66, 5345.
23. X.-S. Wang, D.-Q. Shi, Y.-L. Li, H. Chen, X.-Y. Wei, and Z. M. Zong, Synth. Commun., 2005, 35, 97;
P. Zhang, Y.-D. Yu, and Z.-H. Zhang, Synth. Commun., 2008, 38, 4474.
24. M. M. Sprung, Chem. Rev., 1940, 26, 297.
25. P. S. Chittilapilly and K. K. M. Yusuff, Indian J. Chem., 2008, 47A, 848.
26. X.-S. Wang, M.-M. Zhang, Z.-S. Zeng, D.-Q. Shi, S.-J. Tu, X.-Y. Wei, and Z.-M. Zong, Tetrahedron
Lett., 2005, 46, 7169.